Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD)

NCT01757574 · clinicaltrials.gov ↗
PHASE4
Phase
WITHDRAWN
Status
OTHER
Sponsor class

Stopped At the request of the global principal investigator, no subjects were enrolled in this study at any site.

Conditions

Interventions

Sponsor

Johns Hopkins University

Collaborators